文献速递白血病造血干细胞移植与细胞治疗

极高危急性淋巴细胞白血病儿童移植前微小残留病负荷低:NOPHO ALL2008经验

Low burden of minimal residual disease prior to transplantation in children with very high risk acute lymphoblastic leukaemia: The NOPHO ALL2008 experience.
PubMed 文献 · Br J Haematol · 2019-01-24

基于人群的北欧/波罗的海NOPHO ALL2008方案对高危急性淋巴细胞白血病患儿采用微小残留病(MRD)驱动分层和强烈一线化疗,移植前MRD阳性者复发累积发生率为23.5%,MRD阴性者为5.1%,MRD是唯一与复发显著相关的变量。

要点

  • 移植前MRD阳性患儿复发累积发生率为23.5%,MRD阴性者为5.1%,差异有统计学意义。
  • MRD是唯一与复发显著相关的变量(风险比9.1,95%CI 1.6-51.0,P=0.012)。
  • 两组非复发死亡率无差异,无病生存率分别为85.6%和67.4%。

核心结论

  • NOPHO区块治疗有效减少了残留白血病,结合现代移植流程,即使在移植前MRD阳性的患儿中也获得了高生存率。

研究设计与样本

  • 基于人群的北欧/波罗的海急性淋巴细胞白血病NOPHO ALL2008方案研究,纳入接受造血干细胞移植的71名儿童。

主要发现

  • 71名儿童在接受至少三个高危区块后接受移植,其中46例在诱导结束时MRD≥5%。
  • 10例被分层至移植但未移植,12例无方案指征而接受移植。
  • 69例有可评估移植前MRD结果的患者中,22例MRD阳性,其中1例MRD≥10^-3。
  • 中位随访5.5年后,MRD阳性患者复发累积发生率为23.5%(95%CI 10.5-47.7),MRD阴性患者为5.1%(95%CI 1.3-19.2),P=0.02。
  • MRD是唯一与复发显著相关的变量(风险比9.1,95%CI 1.6-51.0,P=0.012);两组非复发死亡率无差异,无病生存率分别为85.6%(95%CI 75.4-97.2)和67.4%(95%CI 50.2-90.5)。

关键数值与推荐

  • 诱导结束时MRD≥5%或巩固结束时或两个高危区块后MRD≥10^-3的患者有资格在首次缓解期接受造血干细胞移植。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The population-based Nordic/Baltic acute lymphoblastic leukaemia (ALL) Nordic Society for Paediatric Haematology and Oncology (NOPHO) ALL2008 protocol combined minimal residual disease (MRD)-driven treatment stratification with very intense first line chemotherapy for patients with high risk ALL. Patients with MRD ≥5% at end of induction or ≥10-3 at end of consolidation or following two high risk blocks were eligible for haematopoietic cell transplantation (HCT) in first remission. After at least three high risk blocks a total of 71 children received HCT, of which 46 had MRD ≥5% at end of induction. Ten patients stratified to HCT were not transplanted; 12 received HCT without protocol indication. Among 69 patients with evaluable pre-HCT MRD results, 22 were MRD-positive, one with MRD ≥10-3 . After a median follow-up of 5·5 years, the cumulative incidence of relapse was 23·5% (95% confidence interval [CI]: 10·5-47·7) for MRD-positive versus 5·1% (95% CI: 1·3-19·2), P = 0·02) for MRD-negative patients. MRD was the only variable significantly associated with relapse (hazard ratio 9·1, 95% CI: 1·6-51·0, P = 0·012). Non-relapse mortality did not differ between the two groups, resulting in disease-free survival of 85·6% (95% CI: 75·4-97·2) and 67·4% (95% CI: 50·2-90·5), respectively. In conclusion, NOPHO block treatment efficiently reduced residual leukaemia which, combined with modern transplant procedures, provided high survival rates, also among pre-HCT MRD-positive patients.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Ifversen M, Turkiewicz D, Marquart HV, et al. Low burden of minimal residual disease prior to transplantation in children with very high risk acute lymphoblastic leukaemia: The NOPHO ALL2008 experience. Br J Haematol. 2019. PMID: 30680711. doi:10.1111/bjh.15761

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。